The conducted research has revealed that the Cancer Aging Research Group (CARG) score – a tool used to estimate the risk of severe chemotherapy-related side effects for patients – is not robust when used in an older UK population.
Research experts from Leeds Teaching Hospitals NHS Trust, the University of Dundee and across the UK, found that the CARG score was unable to reliably predict toxicity in patients aged over 65 who were receiving chemotherapy for the first time. The team were also able to identify widespread frailty among patients, which is important given the current lack of routine frailty assessment in the UK’s cancer population. The findings have been published in the journal BMJ Oncology.
The CARG score was developed to help predict severe chemotherapy-induced toxicity risk in older adults. The score utilises several performance markers from a patient, such as hearing and physical capabilities, in conjunction with personal data such as weight, height and cancer type to estimate the risk of severe chemotherapy-related side effects.
While recommended for use by international organisations, including the American Society of Clinical Oncology (ASCO), the CARG score had not previously been assessed prospectively in a UK population.
In addition, it has been established for some time that older adults and those with co-existing frailty are more vulnerable to chemotherapy toxicity. However, it was not previously known how common frailty was in older adults receiving chemotherapy in the UK.
The Tolerance Of Anti-cancer Systemic Therapy In the Elderly, or “TOASTIE”, study recruited 339 UK patients, all with a minimum age of 65 years-old. Just over half had been diagnosed with gastrointestinal tumours, while others living with gynaecological, urological, lung and breast cancers were also included.
Analysis of the TOASTIE study data identified a high prevalence of frailty and revealed that the CARG score was unable to predict risk of high-grade toxicity, with the research team concluding that it cannot be considered a robust toxicity prediction tool in an older UK population. In contrast, frailty screening tools such as the Rockwood Clinical Frailty Scale, which measures frailty based on clinical judgement, had predictive value.
Dr Mark Baxter, from Dundee’s School of Medicine, said, “We are seeing an increasing older cancer population throughout the world, however, the availability of data relating to older adults with cancer is limited.
“This is the first multicentre study in the UK to prospectively report the demographics and pre-existing frailty of a real-world cohort of patients across a range of solid organ tumours receiving chemotherapy.
“Analysis of our data found that pre-existing frailty is common and the CARG score was unable to accurately predict toxicity levels in patients.
“The ultimate goal is to provide personalised care for each individual patient we see in clinic. By identifying and assessing frailty in more detail, we can better predict who is more likely to experience side effects. As such, we can have more informed discussions around management decisions.
“There is also now good evidence that targeted interventions based on the findings of the frailty assessment results in better patient outcomes.
“There is a need to develop geriatric oncology services within Scotland and the UK. We also need to carry out more research that would allow us to develop a better standard of predictive tools, which would ultimately improve patient outcomes.”